1,335 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by Collaborative Fund Advisors LLC

Collaborative Fund Advisors LLC acquired a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the 3rd quarter, HoldingsChannel reports. The firm acquired 1,335 shares of the company’s stock, valued at approximately $489,000.

Other institutional investors have also added to or reduced their stakes in the company. Mather Group LLC. lifted its stake in BeOne Medicines by 192.0% during the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock worth $27,000 after purchasing an additional 48 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of BeOne Medicines by 39.5% in the 3rd quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock valued at $44,000 after purchasing an additional 34 shares in the last quarter. Provenance Wealth Advisors LLC bought a new position in shares of BeOne Medicines in the 3rd quarter valued at $106,000. Parallel Advisors LLC raised its holdings in shares of BeOne Medicines by 24.0% during the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after buying an additional 68 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of BeOne Medicines by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after buying an additional 52 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at BeOne Medicines

In related news, COO Xiaobin Wu sold 280 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total value of $106,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 54,892 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total transaction of $19,659,569.80. Following the sale, the chief executive officer owned 240,743 shares of the company’s stock, valued at $86,222,105.45. This trade represents a 18.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 376,373 shares of company stock valued at $134,848,154. 6.19% of the stock is owned by corporate insiders.

BeOne Medicines Trading Up 6.4%

Shares of ONC stock opened at $377.78 on Thursday. The firm has a market capitalization of $41.48 billion, a P/E ratio of 66.51 and a beta of 0.63. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $388.66. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $362.57 and its 200 day simple moving average is $325.73.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 EPS for the current fiscal year.

Analyst Ratings Changes

ONC has been the subject of several recent analyst reports. Truist Financial upped their price objective on BeOne Medicines from $418.00 to $420.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Royal Bank Of Canada boosted their target price on BeOne Medicines from $450.00 to $459.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, BeOne Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $412.26.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.